-
The World Journal of Biological... Aug 2018
Topics: Antidepressive Agents; Depressive Disorder; Humans
PubMed: 29938569
DOI: 10.1080/15622975.2018.1485832 -
Tidsskrift For Den Norske Laegeforening... Mar 2020
Topics: Depressive Disorder; Grief; Humans
PubMed: 32238967
DOI: 10.4045/tidsskr.19.0504 -
Zeitschrift Fur Gerontologie Und... Jun 2015Depression and cognitive disorders, including dementia and mild cognitive impairment, are common disorders in old age. Depression is frequent in dementia, causing... (Review)
Review
Depression and cognitive disorders, including dementia and mild cognitive impairment, are common disorders in old age. Depression is frequent in dementia, causing distress, reducing the quality of life, exacerbating cognitive and functional impairment and increasing caregiver stress. Even mild levels of depression can significantly add to the functional impairment of dementia patients and the severity of psychopathological and neurological impairments increases with increasing severity of depression. Depressive symptoms may be both a risk factor for, as well as a prodrome of dementia. Major depressive syndrome of Alzheimer's disease may be among the most common mood disorders of older adults. Treating depression is therefore a key clinical priority to improve the quality of life both of people with dementia as well as their carergivers. Nonpharmacological approaches and watchful waiting should be attempted first in patients who present with mild to moderate depression and dementia. In cases of severe depression or depression not able to be managed through nonpharmacological means, antidepressant therapy should be considered.
Topics: Alzheimer Disease; Antidepressive Agents; Caregivers; Comorbidity; Cost of Illness; Cross-Sectional Studies; Depressive Disorder; Depressive Disorder, Major; Humans; Quality of Life
PubMed: 25962363
DOI: 10.1007/s00391-015-0898-8 -
Advances in Experimental Medicine and... 2019The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However,... (Review)
Review
The goal of treatment for depressive disorders is complete remission of depressive symptoms with full recovery of social function and prevention of recurrence. However, a large proportion of patients do not experience symptomatic remission after the initial treatment, with even lower rates of remission in the longer treatment term. The main objective of individualized treatment applied in psychiatry is to improve precision in disease diagnosis, prognosis, treatment choices, and treatment response. Diverse approaches and techniques, such as genomics, epigenomics, other omics, neural circuit, and artificial intelligence are related to precision psychiatry. Using biology and computational psychiatry tools to find potential biomarkers, and based on precision psychiatry, patients considered to belong to the same endophenotype will be possible to receive biomarkers-based treatment and better prognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particular attention to biomarkers and the development of new technologies in depressive disorders, which will help disease complete remission and functional recovery, seek better lives for patients suffered with depressive disorders.
Topics: Biomarkers; Depressive Disorder; Epigenomics; Humans; Phenotype; Precision Medicine; Psychiatry
PubMed: 31784966
DOI: 10.1007/978-981-32-9271-0_12 -
Bipolar Disorders Nov 2018To evaluate the efficacy and safety of using adjunctive antipsychotics in patients with major depressive disorder. (Review)
Review
OBJECTIVES
To evaluate the efficacy and safety of using adjunctive antipsychotics in patients with major depressive disorder.
METHOD
Studies published since the last Cochrane review conducted in 2010 were identified via a literature search of recognised databases, using the keywords "adjunct*", "augment*", "antipsychotic" and "depression", and systematically evaluated. A targeted review of relevant guidelines was undertaken.
RESULTS
Adjunctive antipsychotics produce a small but significant improvement in depressive symptoms in most studies. Most of the studies focussed on patients with an inadequate response to antidepressants rather than patients with treatment resistant depression. Treatment guidelines were variable but generally supported the use of adjunctive antipsychotics while cautioning about the risk of side effects. Most were non-specific about the length of time adjunctive antipsychotics should be prescribed.
CONCLUSIONS
The studies do not support the routine use of adjunctive antipsychotics in patients with an inadequate response to antidepressants. They may be beneficial when used short-term in patients with treatment resistant depression who have specific symptoms (severe ruminations, melancholia, major sleep disturbance) that appear to respond well to adjunctive antipsychotics. There is no support for long-term use. Research should focus on specifying which symptom profiles are responsive and how adjunctive antipsychotics compare to other strategies in treatment resistant depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Randomized Controlled Trials as Topic; Treatment Outcome
PubMed: 30328223
DOI: 10.1111/bdi.12701 -
International Review of Neurobiology 2017Depression and anxiety are some of the most common comorbidities arising in patients with Parkinson's disease. However, their timely recognition and diagnosis are often... (Review)
Review
Depression and anxiety are some of the most common comorbidities arising in patients with Parkinson's disease. However, their timely recognition and diagnosis are often hindered by overlap with other somatic features and a low rate of self-report. There is a need for greater awareness and for better assessment and treatment options are highly required. Currently available scales can serve as tools to monitor change over time and the effect of interventional strategies. Development of new therapeutic strategies, including nonpharmacological approaches such as transcranial magnetic stimulation and deep brain stimulation, may provide alternatives to currently available treatment approaches. In this chapter we will give an overview of the most recent advances in the diagnosis and treatment of these important nonmotor symptoms.
Topics: Anxiety Disorders; Depressive Disorder; Humans; Parkinson Disease
PubMed: 28802935
DOI: 10.1016/bs.irn.2017.05.024 -
Issues in Mental Health Nursing Jan 2020
Topics: Depressive Disorder; Humans
PubMed: 31951802
DOI: 10.1080/01612840.2019.1685345 -
Fortschritte Der Neurologie-Psychiatrie May 2018Depressive disorders are associated with various neurobiological alterations like hyperactivity of the hypothalamic-pituitary-adrenal axis, altered neuroplasticity and... (Review)
Review
Depressive disorders are associated with various neurobiological alterations like hyperactivity of the hypothalamic-pituitary-adrenal axis, altered neuroplasticity and altered circadian rhythms. Relating to the circadian symptoms, a process is adopted in which individual genetic factors together with social, psychological and physical stressors may lead to a decompensation of the circadian system. The causal connections between depressive disorders and disturbed circadian rhythms have not been completely clarified. Chronobiological therapy is based on these disturbed processes. For the treatment of the circadian symptoms, various scientifically tested chronotherapeutics are available with however different effectiveness and evidence like light therapy or sleep deprivation. The successful treatment of depression also frequently leads to a improvement in altered circadian rhythm.
Topics: Chronobiology Disorders; Circadian Rhythm; Depressive Disorder; Humans; Phototherapy
PubMed: 29843180
DOI: 10.1055/s-0043-123069 -
Therapeutische Umschau. Revue... Aug 2021Post stroke depression Post stroke depression is a common psychiatric disorder after a cerebrovascular insult. It effects the outcome of the rehabilitation after the...
Post stroke depression Post stroke depression is a common psychiatric disorder after a cerebrovascular insult. It effects the outcome of the rehabilitation after the stroke and leads to an increased mortality. The symptomatic description of the depressive symptoms is done according to the ICD-10 criteria. The following article aims to provide an overview of the etiologic theories, diagnostic approaches, and therapeutic strategies regarding PSD.
Topics: Depression; Depressive Disorder; Humans; Stroke
PubMed: 34291664
DOI: 10.1024/0040-5930/a001274 -
American Journal of Psychoanalysis Sep 2016This paper discusses ideas about depression as a paradigmatic symptom of contemporaneous psychological suffering and makes a comparison between depression and...
This paper discusses ideas about depression as a paradigmatic symptom of contemporaneous psychological suffering and makes a comparison between depression and melancholia. The ideas we describe were stimulated by two comparative studies that were conducted based on an analysis of how depressed subjects relate to the concept of desire, their feelings of shame and their self-image in today's age.
Topics: Defense Mechanisms; Depression; Depressive Disorder; Humans; Narcissism; Self Concept; Shame
PubMed: 28638134
DOI: 10.1057/s11231-016-9047-4